-
Z-VAD-FMK Workflow for Apoptosis Research
2026-09-01
Use Z-VAD-FMK to distinguish caspase-dependent apoptosis from broader drug-induced loss of viability, with a practical workflow for EGFR-inhibitor and immune-cell studies. This guide combines solvent handling, kinetic controls, orthogonal readouts, and troubleshooting for more defensible apoptosis inhibition experiments.
-
Naftifine HCl: Mechanism and Research Workflow
2026-09-01
Naftifine HCl is an allylamine antifungal agent that inhibits fungal squalene 2,3-epoxidase and disrupts ergosterol biosynthesis. The product dossier reports a 323.86 g/mol hydrochloride salt, high purity above 98%, defined organic-solvent solubility, and storage at −20°C.
-
Nigericin for pH and Mitochondrial Assays
2026-08-31
Nigericin is a potassium/hydrogen ion carrier for experimentally controlled intracellular pH modulation, mitochondrial membrane ion transport, and GSDMD-linked cell-death studies. This practical guide connects formulation, dose finding, orthogonal readouts, and antibiotic-metabolism research without overstating evidence across model systems.
-
NF 449 and Platelet P2 Receptor Inhibition
2026-08-31
The reference study established NF 449 as a useful antagonist for separating platelet P2X1 signaling from P2Y1 and P2Y12 responses. Its combination of receptor-level pharmacology, platelet aggregation assays, and mouse thrombosis models showed that selective P2X1 blockade can reduce thromboembolic activity while preserving bleeding time under the tested conditions.
-
YY1 Haploinsufficiency Rewires Corticogenesis
2026-08-30
This preprint uses patient-derived iPSCs, 2D and 3D neural models, single-cell multiomics, imaging, and gene-regulatory network reconstruction to show how YY1 haploinsufficiency disrupts corticogenesis in a cell-type-specific manner. Its central contribution is linking intrinsic defects in neural progenitors and neurons with a non-cell-autonomous inflammatory response in neighboring astrocytes, providing a mechanistic framework for Gabriele-de Vries syndrome.
-
PUFA-PL Biosynthesis in Rice Blast Pathogenicity
2026-08-29
A 2024 Mycology study identifies Fad2 and Acsl4 as lipid-biosynthetic enzymes that support Magnaporthe oryzae pathogenic development through PUFA-containing phospholipids and ferroptosis-associated lipid peroxidation. Its combined genetic, lipidomic, chemical-rescue, and protein-interaction evidence provides a mechanistic framework for studying fungal cell death as a potential rice blast control target.
-
Nystatin (Fungicidin) in Translational Assays
2026-08-28
Nystatin (Fungicidin) combines ergosterol-targeted membrane disruption with practical utility in Candida, mycoplasma, adhesion, resistance, and formulation studies. This guide shows how to build reproducible antifungal assays and how nanoparticle-uptake findings can inform—but not substitute for—future delivery experiments.
-
Oteseconazole (VT-1161) Assay Workflows
2026-08-28
Build more informative Candida susceptibility studies with Oteseconazole (VT-1161), a selective fungal CYP51 inhibitor suited to species panels, resistance profiling, and mechanism-linked validation. This guide combines practical dilution workflows with transporter-aware interpretation for translational antifungal research.
-
Hepatic sEH, Nrf2, and Osteoclastogenesis in Osteoporosis
2026-08-27
A recent Free Radical Biology and Medicine study identifies a liver–bone signaling axis in which hepatic soluble epoxide hydrolase alters circulating 14,15-EET and 14,15-DHET, suppressing Nrf2 activity and promoting osteoclastogenesis. By combining patient samples, an ovariectomy-induced mouse model, liver-specific knockdown, pharmacological inhibition, and transcriptomics, the study connects epoxyeicosatrienoic acids metabolism with redox imbalance and bone loss.
-
1-Phenyl-2-Pentanol and Liver Fibrosis
2026-08-27
The reference study identifies 1-phenyl-2-pentanol from Moringa oleifera leaves as an inhibitor of profibrotic activation in TGF-β1-stimulated LX-2 hepatic stellate cells. By combining fibrosis-marker analysis with proteomics and molecular docking, the work connects reduced extracellular-matrix signaling with possible modulation of the Wnt/β-catenin pathway while highlighting the need for in vivo validation.
-
JAK Inhibitors and Endothelial Cardiovascular Risk
2026-08-26
A 2025 ACR Open Rheumatology study compared six JAK inhibitors in cytokine-stimulated human endothelial cells, separating anti-inflammatory effects from changes linked to adhesion, coagulation, and cell death. The results show that reducing IL-6 does not necessarily normalize endothelial thrombo-inflammatory or viability pathways, highlighting the limits of treating JAK inhibitors as a uniform class.
-
Griseofulvin Workflows for Microtubule Assays
2026-08-26
Build reproducible fungal mitosis, microtubule dynamics, and aneugenicity experiments with Griseofulvin. This guide combines solvent handling, time-course design, mechanistic controls, and troubleshooting for research teams moving from phenotype to pathway-level evidence.
-
Colistin–Gamithromycin Synergy in P. multocida
2026-08-25
This study evaluated colistin–gamithromycin combinations against Pasteurella multocida using susceptibility testing, time-kill experiments, pharmacokinetics, and a neutropenic murine pneumonia model. Its main contribution is showing that synergy was strongest in isolates with higher colistin MICs, while PK/PD analysis supported substantially lower gamithromycin exposure during combination therapy.
-
RSL3: A GPX4 Inhibitor for Ferroptosis Assays
2026-08-25
Explore how RSL3, a glutathione peroxidase 4 inhibitor, converts redox vulnerability into a rigorously testable ferroptosis phenotype. This article connects GPX4 perturbation with TEAD2 biology, RAS-driven models, and evidence-based assay design.
-
Fenofibrate Workflows for PPARα-YAP Research
2026-08-24
Build reproducible Fenofibrate assays around PPARα engagement, lipid metabolism, and downstream YAP signaling rather than relying on viability readouts alone. This guide connects stock preparation, time-resolved cell workflows, liver enlargement models, and cancer assays with practical troubleshooting for stronger mechanistic interpretation.